Pharmacological Comparison of Dostarlimab and Pembrolizumab in Metastatic Non-Small Cell Lung Cancer in PERLA

被引：0

作者：

Samant, T. S. ^{[1
]}

Struemper, H. ^{[2
]}

Franzese, R. C. ^{[1
]}

Goulooze, B. ^{[3
]}

Muliaditan, M. ^{[3
]}

Melhem, M. ^{[4
]}

Ghosh, S. ^{[1
]}

Fastenrath, M. ^{[5
]}

Stjepanovic, N. ^{[6
]}

Szijgyarto, Z. ^{[7
]}

Rathi, C. ^{[1
]}

Mantero, A. ^{[1
]}

Hanafin, P. ^{[1
]}

Zajic, S. ^{[1
]}

Yanamandra, N. ^{[1
]}

Chung, C-W.

Vlahovic, G.

机构：

[1] GSK, Collegeville, PA USA

[2] GSK, Durham, NC USA

[3] LAP&P Consultants, Leiden, Netherlands

[4] GSK, Waltham, MA USA

[5] GSK, London, England

[6] GSK, Baar, Switzerland

[7] GSK, Stevenage, Herts, England

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

基金：

芬兰科学院;

关键词：

mNSCLC; Tumor Size-Overall Survival Modeling; Clinical Pharmacology;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P4.11E.28

引用

页码：S407 / S408

页数：2

共 50 条

[31] The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer
Mazarico Gallego, Jose Ma
Herrera Juarez, Mercedes
Paz-Ares, Luis
EXPERT OPINION ON DRUG SAFETY, 2020, 19 (03) : 233 - 242
[32] Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
Vachhani, Pankit
Chen, Hongbin
ONCOTARGETS AND THERAPY, 2016, 9 : 5855 - 5866
[33] East Anglian audit of pembrolizumab in non-small cell lung cancer
Jackson, A. H.
Fenn, R.
Shotton, R.
Williams, A.
Treece, S.
Gkogkou, P.
Tasigiannopoulos, Z.
Gilligan, D.
Yip, K.
LUNG CANCER, 2018, 115 : S39 - S39
[34] Pembrolizumab toxicity in non-small cell lung cancer: a retrospective analysis
Keast, Mary
Button, Mick
Case, Amy
Iqbal, Sahar
Namelo, Clara
Powell, Ceri
Powell, James
Shaw, Paul
Cox, Samantha
LUNG CANCER, 2022, 165 : S37 - S38
[35] Neoadjuvant Pembrolizumab for Early Stage Non-Small Cell Lung Cancer
Bar, J.
Urban, D.
Redinsky, I.
Ackerstein, A.
Daher, S.
Kamer, I.
Onn, A.
Shulimzon, T.
Peled, M.
Zeitlin, N.
Kremer, R.
Raskin, S.
Ben-Nun, A.
Perelman, M.
Ofek, E.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S865 - S866
[36] The role of pembrolizumab in the treatment of advanced non-small cell lung cancer
Santabarbara, Giuseppe
Maione, Paolo
Rossi, Antonio
Palazzolo, Giovanni
Gridelli, Cesare
ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (11)
[37] An audit of pembrolizumab use in non-small cell lung cancer in Nottingham
Suyanto, S.
Yeo, D.
Khan, S.
LUNG CANCER, 2018, 115 : S39 - S39
[38] Cobolimab with Dostarlimab and Docetaxel in Patients with Advanced Non-small Cell Lung Cancer (NSCLC): COSTAR Lung
Kim, H. R.
Gridelli, C.
Kapur, D.
Tufman, A.
Felip, E.
Velcheti, V.
Kim, Y. J.
Goetze, T. O.
Lopez, P. Garrido
Corre, R.
Penkov, K.
Anjum, R.
Di Pace, B.
Liu, W.
Borgovan, T.
Ledger, D.
Carver, J.
Waszak, A.
Dhar, A.
Novello, S.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S109 - S110
[39] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
Gandhi, L.
Rodriguez-Abreu, D.
Gadgeel, S.
Esteban, E.
Felip, E.
De Angelis, F.
Domine, M.
Clingan, P.
Hochmair, M. J.
Powell, S. F.
Cheng, S. Y. -S.
Bischoff, H. G.
Peled, N.
Grossi, F.
Jennens, R. R.
Reck, M.
Hui, R.
Garon, E. B.
Boyer, M.
Rubio-Viqueira, B.
Novello, S.
Kurata, T.
Gray, J. E.
Vida, J.
Wei, Z.
Yang, J.
Raftopoulos, H.
Pietanza, M. C.
Garassino, M. C.
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22): : 2078 - 2092
[40] Prognostic Value of Change in Platelet Volume for Patients with Metastatic Non-small Cell Lung Cancer Treated with Pembrolizumab
Li, M.
Zhao, S.
Chian, K.
Chakravarthy, K.
Kwon, H.
Gauntner, T.
Jones, N.
Secor, A.
Das, P.
Surya, N.
Zehr, B.
Spakowicz, D.
Wei, L.
He, K.
Alahmadi, A.
Memmott, R.
Kaufman, J.
Shields, P. G.
Li, Z.
Carbone, D. P.
Presley, C. J.
Otterson, G. A.
Owen, D. H.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S240 - S241

← 1 2 3 4 5 →